AstraZeneca Pays $600 Million for Lung Cancer Drug in China

Pharmaceutical giant AstraZeneca has paid $600 million to license a lung cancer drug candidate from a China-based biotechnology firm. Under the agreement, AstraZeneca has obtained global development and commercialization rights for the drug. The drug is being developed as a targeted therapy for non-small cell lung cancer (NSCLC), a common type of cancer. AstraZeneca stated that the candidate could be effective in patients resistant to existing treatments. The payment includes $600 million upfront and additional milestone-based payments. AstraZeneca emphasized that this deal is part of its strategy to strengthen its oncology portfolio. Analysts note that such licensing agreements allow large pharmaceutical companies to access innovative treatments while reducing R&D costs. AstraZeneca's growing presence in the Chinese market is also noteworthy. This is not investment advice.

📊 AZN — Piyasa Yorumu

▼ down · 70%

The stock experienced a sharp decline of 10.7% from its last closing price, with the RSI dropping to 27, entering oversold territory. MACD values are in negative territory and trading below the signal line, indicating weak short-term momentum. Trading below the 20-day and 50-day moving averages further weakens the technical outlook. The $600 million payment mentioned in the news could create short-term pressure on the company's cash flow and reinforce the current downtrend. However, the oversold zone may attract some buying interest, so while bearish expectations are high, the possibility of a sharp rebound should not be ruled out.

RSI 14

27.1

MACD

-4.31

24h Δ

-10.75%

Canlı Grafikler